JP2008535873A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008535873A5 JP2008535873A5 JP2008505738A JP2008505738A JP2008535873A5 JP 2008535873 A5 JP2008535873 A5 JP 2008535873A5 JP 2008505738 A JP2008505738 A JP 2008505738A JP 2008505738 A JP2008505738 A JP 2008505738A JP 2008535873 A5 JP2008535873 A5 JP 2008535873A5
- Authority
- JP
- Japan
- Prior art keywords
- adrenergic receptor
- composition
- receptor agonist
- beta
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000048 adrenergic agonist Substances 0.000 claims 22
- 239000000203 mixture Substances 0.000 claims 22
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims 21
- 239000003814 drug Substances 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 8
- -1 C 1-6- Alkoxyl Chemical group 0.000 claims 7
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 6
- 238000011200 topical administration Methods 0.000 claims 6
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims 5
- 125000002877 alkyl aryl group Chemical group 0.000 claims 4
- 206010025135 lupus erythematosus Diseases 0.000 claims 4
- 150000003254 radicals Chemical class 0.000 claims 4
- 150000001721 carbon Chemical group 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 229960002052 salbutamol Drugs 0.000 claims 3
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims 2
- TWUSDDMONZULSC-QMTHXVAHSA-N (1s,2r)-2-(tert-butylamino)-1-(2,5-dimethoxyphenyl)propan-1-ol Chemical compound COC1=CC=C(OC)C([C@H](O)[C@@H](C)NC(C)(C)C)=C1 TWUSDDMONZULSC-QMTHXVAHSA-N 0.000 claims 2
- UWYLQWLJGMLJQF-UHFFFAOYSA-N 1-(4-aminophenyl)-2-(butan-2-ylamino)ethanol Chemical group CCC(C)NCC(O)C1=CC=C(N)C=C1 UWYLQWLJGMLJQF-UHFFFAOYSA-N 0.000 claims 2
- XTJMTDZHCLBKFU-UHFFFAOYSA-N 2-(tert-butylamino)-1-(2-fluorophenyl)ethanol Chemical compound CC(C)(C)NCC(O)C1=CC=CC=C1F XTJMTDZHCLBKFU-UHFFFAOYSA-N 0.000 claims 2
- BUXRLJCGHZZYNE-UHFFFAOYSA-N 2-amino-5-[1-hydroxy-2-(propan-2-ylamino)ethyl]benzonitrile Chemical compound CC(C)NCC(O)C1=CC=C(N)C(C#N)=C1 BUXRLJCGHZZYNE-UHFFFAOYSA-N 0.000 claims 2
- MPCPSVWSWKWJLO-UHFFFAOYSA-N 4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenol Chemical compound CC(C)NCC(O)C1=CC=C(O)C=C1 MPCPSVWSWKWJLO-UHFFFAOYSA-N 0.000 claims 2
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 claims 2
- HUYWAWARQUIQLE-UHFFFAOYSA-N Isoetharine Chemical compound CC(C)NC(CC)C(O)C1=CC=C(O)C(O)=C1 HUYWAWARQUIQLE-UHFFFAOYSA-N 0.000 claims 2
- VPMWDFRZSIMDKW-YJYMSZOUSA-N Salmefamol Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 VPMWDFRZSIMDKW-YJYMSZOUSA-N 0.000 claims 2
- ZSTCZWJCLIRCOJ-DGCLKSJQSA-N Zilpaterol Chemical compound O[C@H]1[C@H](NC(C)C)CCN2C(=O)NC3=CC=CC1=C32 ZSTCZWJCLIRCOJ-DGCLKSJQSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims 2
- 229950004242 amiterol Drugs 0.000 claims 2
- RDUHXGIIUDVSHR-UHFFFAOYSA-N bamethan Chemical compound CCCCNCC(O)C1=CC=C(O)C=C1 RDUHXGIIUDVSHR-UHFFFAOYSA-N 0.000 claims 2
- 229960004162 bamethan Drugs 0.000 claims 2
- 229960001386 carbuterol Drugs 0.000 claims 2
- KEMXXQOFIRIICG-UHFFFAOYSA-N carbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(NC(N)=O)=C1 KEMXXQOFIRIICG-UHFFFAOYSA-N 0.000 claims 2
- 229950010971 cimaterol Drugs 0.000 claims 2
- 229960001117 clenbuterol Drugs 0.000 claims 2
- STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 claims 2
- 229950010161 deterenol Drugs 0.000 claims 2
- 239000000839 emulsion Substances 0.000 claims 2
- 229950002456 etafedrine Drugs 0.000 claims 2
- IRVLBORJKFZWMI-JQWIXIFHSA-N etafedrine Chemical compound CCN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1 IRVLBORJKFZWMI-JQWIXIFHSA-N 0.000 claims 2
- LENNRXOJHWNHSD-UHFFFAOYSA-N ethylnorepinephrine Chemical compound CCC(N)C(O)C1=CC=C(O)C(O)=C1 LENNRXOJHWNHSD-UHFFFAOYSA-N 0.000 claims 2
- 229960002267 ethylnorepinephrine Drugs 0.000 claims 2
- 229950009061 flerobuterol Drugs 0.000 claims 2
- 239000006260 foam Substances 0.000 claims 2
- 229960002848 formoterol Drugs 0.000 claims 2
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims 2
- OXLZNBCNGJWPRV-UHFFFAOYSA-N hexoprenaline Chemical compound C=1C=C(O)C(O)=CC=1C(O)CNCCCCCCNCC(O)C1=CC=C(O)C(O)=C1 OXLZNBCNGJWPRV-UHFFFAOYSA-N 0.000 claims 2
- 229960001268 isoetarine Drugs 0.000 claims 2
- JSJCTEKTBOKRST-UHFFFAOYSA-N mabuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(C(F)(F)F)=C1 JSJCTEKTBOKRST-UHFFFAOYSA-N 0.000 claims 2
- 229950004407 mabuterol Drugs 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 229960002748 norepinephrine Drugs 0.000 claims 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims 2
- 239000007764 o/w emulsion Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229960002288 procaterol Drugs 0.000 claims 2
- FKNXQNWAXFXVNW-BLLLJJGKSA-N procaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)[C@@H](NC(C)C)CC FKNXQNWAXFXVNW-BLLLJJGKSA-N 0.000 claims 2
- 229950001879 salmefamol Drugs 0.000 claims 2
- 208000011834 subacute cutaneous lupus erythematosus Diseases 0.000 claims 2
- 229960000195 terbutaline Drugs 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- 229960000960 zilpaterol Drugs 0.000 claims 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 claims 1
- NUBLQEKABJXICM-FQEVSTJZSA-N (1r)-1-(4-amino-3,5-dichlorophenyl)-2-[6-(2-pyridin-2-ylethoxy)hexylamino]ethanol Chemical compound C1=C(Cl)C(N)=C(Cl)C=C1[C@@H](O)CNCCCCCCOCCC1=CC=CC=N1 NUBLQEKABJXICM-FQEVSTJZSA-N 0.000 claims 1
- NDAUXUAQIAJITI-LBPRGKRZSA-N (R)-salbutamol Chemical group CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 claims 1
- YREYLAVBNPACJM-UHFFFAOYSA-N 2-(tert-butylamino)-1-(2-chlorophenyl)ethanol Chemical compound CC(C)(C)NCC(O)C1=CC=CC=C1Cl YREYLAVBNPACJM-UHFFFAOYSA-N 0.000 claims 1
- RTLJQOLVPIGICL-UHFFFAOYSA-N 4-[2-(tert-butylamino)-1-hydroxyethyl]-2-(methylsulfonylmethyl)phenol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CS(C)(=O)=O)=C1 RTLJQOLVPIGICL-UHFFFAOYSA-N 0.000 claims 1
- KOTMQCNDGLTIHR-UHFFFAOYSA-N 4-[2-[[4-(benzimidazol-1-yl)-2-methylbutan-2-yl]amino]-1-hydroxyethyl]-3-fluorophenol Chemical compound C1=NC2=CC=CC=C2N1CCC(C)(C)NCC(O)C1=CC=C(O)C=C1F KOTMQCNDGLTIHR-UHFFFAOYSA-N 0.000 claims 1
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims 1
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 claims 1
- RSDQHEMTUCMUPQ-UHFFFAOYSA-N 5-[1-hydroxy-2-(propan-2-ylamino)ethyl]quinolin-8-ol Chemical compound C1=CC=C2C(C(O)CNC(C)C)=CC=C(O)C2=N1 RSDQHEMTUCMUPQ-UHFFFAOYSA-N 0.000 claims 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 208000006802 Lupus erythematosus panniculitis Diseases 0.000 claims 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000011830 chronic cutaneous lupus erythematosus Diseases 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 229960001022 fenoterol Drugs 0.000 claims 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 150000002337 glycosamines Chemical class 0.000 claims 1
- 150000004678 hydrides Chemical group 0.000 claims 1
- 229960004078 indacaterol Drugs 0.000 claims 1
- QZZUEBNBZAPZLX-QFIPXVFZSA-N indacaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 QZZUEBNBZAPZLX-QFIPXVFZSA-N 0.000 claims 1
- 229940039009 isoproterenol Drugs 0.000 claims 1
- 239000011499 joint compound Substances 0.000 claims 1
- 229940040145 liniment Drugs 0.000 claims 1
- 239000000865 liniment Substances 0.000 claims 1
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- HHRNQOGXBRYCHF-UHFFFAOYSA-N n-[2-hydroxy-5-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl]methanesulfonamide Chemical compound CC(C)NCC(O)C1=CC=C(O)C(NS(C)(=O)=O)=C1 HHRNQOGXBRYCHF-UHFFFAOYSA-N 0.000 claims 1
- 229950008345 nardeterol Drugs 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 229960002657 orciprenaline Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229950004618 picumeterol Drugs 0.000 claims 1
- 229950000298 quinprenaline Drugs 0.000 claims 1
- 229960002720 reproterol Drugs 0.000 claims 1
- WVLAAKXASPCBGT-UHFFFAOYSA-N reproterol Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CCCNCC(O)C1=CC(O)=CC(O)=C1 WVLAAKXASPCBGT-UHFFFAOYSA-N 0.000 claims 1
- 229960004017 salmeterol Drugs 0.000 claims 1
- 229950010289 soterenol Drugs 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 229950007862 sulfonterol Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229940041677 topical spray Drugs 0.000 claims 1
- 229960000859 tulobuterol Drugs 0.000 claims 1
- 239000007762 w/o emulsion Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200500529 | 2005-04-13 | ||
| DKPA200500529 | 2005-04-13 | ||
| PCT/DK2006/050013 WO2006108424A2 (en) | 2005-04-13 | 2006-04-12 | Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008535873A JP2008535873A (ja) | 2008-09-04 |
| JP2008535873A5 true JP2008535873A5 (enExample) | 2009-05-28 |
| JP5021621B2 JP5021621B2 (ja) | 2012-09-12 |
Family
ID=36703472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008505738A Expired - Fee Related JP5021621B2 (ja) | 2005-04-13 | 2006-04-12 | 皮膚の結合組織病を治療するためのβ−２アドレナリン受容体作動薬 |
Country Status (28)
| Country | Link |
|---|---|
| US (4) | US8426475B2 (enExample) |
| EP (1) | EP1719507B1 (enExample) |
| JP (1) | JP5021621B2 (enExample) |
| KR (1) | KR101355422B1 (enExample) |
| CN (1) | CN101203214B (enExample) |
| AR (1) | AR054249A1 (enExample) |
| AT (1) | ATE473735T1 (enExample) |
| AU (1) | AU2006233502B2 (enExample) |
| BR (1) | BRPI0609361A2 (enExample) |
| CA (1) | CA2604758C (enExample) |
| CY (1) | CY1111541T1 (enExample) |
| DE (1) | DE602006015387D1 (enExample) |
| DK (1) | DK1719507T3 (enExample) |
| EA (1) | EA016082B1 (enExample) |
| ES (1) | ES2348920T3 (enExample) |
| HR (1) | HRP20100552T1 (enExample) |
| IL (1) | IL186491A (enExample) |
| MX (1) | MX2007012794A (enExample) |
| MY (1) | MY147864A (enExample) |
| NO (1) | NO331211B1 (enExample) |
| NZ (1) | NZ562940A (enExample) |
| PL (1) | PL1719507T3 (enExample) |
| PT (1) | PT1719507E (enExample) |
| RS (1) | RS51464B (enExample) |
| SI (1) | SI1719507T1 (enExample) |
| TW (1) | TWI366457B (enExample) |
| WO (1) | WO2006108424A2 (enExample) |
| ZA (1) | ZA200708748B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0604826D0 (en) * | 2006-03-09 | 2006-04-19 | Arakis Ltd | The treatment of inflammatory disorders and pain |
| CA2656312C (en) | 2006-07-10 | 2014-09-09 | Intervet International B.V. | Zilpaterol enantiomer compositions and methods of making and using such compositions |
| GB0624757D0 (en) * | 2006-12-12 | 2007-01-17 | Sosei R & D Ltd | Novel compounds |
| GB0805535D0 (en) * | 2008-03-27 | 2008-04-30 | Univ Leicester | Scar prevention |
| US20120252831A1 (en) * | 2011-03-31 | 2012-10-04 | Mustafa Nevzat Ilac Sanayii A.S. | Compositions of opioid antagonists and methods for treating scleroderma therewith |
| CN102267917B (zh) * | 2011-06-15 | 2013-07-31 | 浙江工业大学 | 一种盐酸甲氧那明的合成方法 |
| JP6209208B2 (ja) * | 2012-05-18 | 2017-10-04 | インターベット インターナショナル ベー． フェー． | ブロイラー鶏の性能向上法 |
| GB2513297A (en) * | 2013-03-08 | 2014-10-29 | Univ Leicester | Methods |
| CN104606177B (zh) * | 2014-11-21 | 2018-02-02 | 苏州君宁新药开发中心有限公司 | 左旋(r)沙丁胺醇制剂在治疗皮肤及粘膜创伤溃疡的药物应用 |
| WO2018000098A1 (en) * | 2016-06-30 | 2018-01-04 | Cipher Pharmaceuticals Inc. | Treatment of inflammatory myopathies |
| CN106580978A (zh) * | 2016-11-30 | 2017-04-26 | 郑州仁宏医药科技有限公司 | 一种治疗皮炎的西药组合物及其应用 |
| CN111315438B (zh) * | 2017-08-10 | 2022-09-27 | 爱肤柔生命科学公司 | 经皮药物递送系统 |
| GB201714745D0 (en) * | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201714734D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201903832D0 (en) | 2019-03-20 | 2019-05-01 | Atrogi Ab | New compounds and methods |
| JP7682097B2 (ja) * | 2019-03-27 | 2025-05-23 | キュラセン セラピューティクス インコーポレイテッド | ベータアドレナリンアゴニスト及びそれを使用する方法 |
| CA3161376A1 (en) | 2019-12-18 | 2021-06-24 | Anthony P. FORD | Methods for improving neurological diseases and disorders |
| CN112300237A (zh) * | 2020-04-13 | 2021-02-02 | 苏州恩泰新材料科技有限公司 | 海豹胆酸的制备方法及其应用 |
| MX2023003569A (es) * | 2020-10-09 | 2023-04-04 | Mc2 Therapeutics Ltd | Tratamiento de padecimientos dermatologicos. |
| CN116236467B (zh) * | 2023-02-07 | 2023-10-27 | 中国人民解放军总医院 | 西马特罗或其衍生物的新用途 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA7468B (en) | 1973-01-16 | 1974-11-27 | J Voorhees | Compositions and treatment of proliferatave skin diseases with phosphodiesterase inhibitors |
| US4284623A (en) * | 1979-11-09 | 1981-08-18 | Beck Lee R | Method of treating inflammation using bovine milk |
| SU895445A1 (ru) * | 1980-05-15 | 1982-01-07 | Военно-Медицинская Краснознаменная Академия Им. С.М.Кирова | Способ лечени кожных форм красной волчанки |
| US4574129A (en) | 1984-01-31 | 1986-03-04 | Bristol-Myers Company | Topical nonsteroidal anti-inflammatory methods |
| JPS61154201A (ja) | 1984-12-26 | 1986-07-12 | Matsushita Electric Ind Co Ltd | 誘電体フイルタ |
| US4699777A (en) | 1985-08-21 | 1987-10-13 | Schering Corporation | Compositions and method for enhancement of the transdermal flux of albuterol with a combination of 1-dodecyl-azacyclopheptan-2-one and urea |
| PH25150A (en) | 1986-06-05 | 1991-03-13 | Ciba Geigy Ag | Novel pharmaceutical preparation for topical application |
| US4980159A (en) | 1989-05-23 | 1990-12-25 | Bristol-Myers Squibb Company | Processes and compositions for the topical application of β-adrenergic agonists for pilomotor effects |
| RU2092105C1 (ru) * | 1989-11-20 | 1997-10-10 | Нижегородский научно-исследовательский кожно-венерологический институт | Способ определения терапевтической тактики у больных очаговой склеродермией и дискоидной красной волчанкой |
| DE4014252A1 (de) * | 1990-05-04 | 1991-11-07 | Boehringer Ingelheim Vetmed | Enantiomerentrennung von cimaterol, (-)-cimaterol und dessen verwendung als arzneimittel oder als leistungsfoerderer |
| US5919827A (en) * | 1990-07-11 | 1999-07-06 | Sepracor Inc. | Method for treating asthma using optically pure R(-) salmeterol |
| WO1992001477A1 (en) | 1990-07-26 | 1992-02-06 | G.D. Searle & Co. | Polymeric drug delivery system |
| US5795564A (en) * | 1991-04-05 | 1998-08-18 | Sepracor, Inc. | Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol |
| GB9107196D0 (en) * | 1991-04-05 | 1991-05-22 | Sandoz Ag | Improvements in or relating to organic compounds |
| JP3294876B2 (ja) | 1992-07-20 | 2002-06-24 | トキコ株式会社 | 給油装置 |
| AU1533495A (en) | 1994-01-12 | 1995-08-01 | Byk Nederland Bv | Phenyl ethanol amine ethers and uses thereof as beta-adreno-receptor agonists |
| JPH07304647A (ja) | 1994-05-09 | 1995-11-21 | Kao Corp | マッサージ用組成物 |
| GB9422306D0 (en) * | 1994-11-04 | 1994-12-21 | Sandoz Ltd | Organic compounds |
| GB9510162D0 (en) * | 1995-05-19 | 1995-07-12 | Bouras Elias | Compositions for the treatment of skin conditions |
| JPH09110674A (ja) | 1995-10-16 | 1997-04-28 | Kao Corp | 浴用剤組成物 |
| FR2740040B1 (fr) | 1995-10-23 | 1997-12-05 | Oreal | Utilisation d'au moins un agoniste beta-adrenergique en tant qu'antagoniste de substance p |
| CA2286913C (en) * | 1997-04-30 | 2008-12-09 | Bridge Pharma, Inc. | Composition and methods using an eutomer |
| US6254882B1 (en) | 1997-09-16 | 2001-07-03 | Sepracor Inc. | Methods and compositions for treating pulmonary disorders using optically pure (S)—salmeterol |
| EP1315735A4 (en) * | 2000-08-31 | 2005-04-06 | Merck & Co Inc | Phosphate derivatives as immunoregulatory compounds |
| WO2002040021A2 (en) | 2000-11-17 | 2002-05-23 | Idenix (Cayman) Limited | Methods for inhibiting the transmission of hiv using topically applied substituted 6-benzyl-4-oxopyrimidines |
| DK1451154T3 (da) | 2001-12-03 | 2008-05-19 | Wyeth Corp | Inhibitorer af cytosolisk phospholipase A2 |
| EP1496917B1 (en) * | 2002-04-19 | 2005-12-07 | Astion Development A/S | Combination of a beta-2 adrenoceptor agonists and an aminosugars and their use for the treatment immunomodulatory disorders |
| WO2003088997A2 (en) | 2002-04-22 | 2003-10-30 | Universiteit Utrecht Holding B.V. | Reduction of unwanted immune reactions |
| AU2003228819A1 (en) | 2002-05-03 | 2003-11-17 | Combinatorx, Incorporated | Combinations for the treatment of inflammatory skin disorders |
| DE10224888A1 (de) | 2002-06-05 | 2003-12-24 | Merck Patent Gmbh | Pyridazinderivate |
| US20040220153A1 (en) | 2002-09-24 | 2004-11-04 | Jost-Price Edward Roydon | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
| AU2003299196A1 (en) * | 2002-09-24 | 2004-04-23 | Combinatorx, Incorporated | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
| US20040229849A1 (en) | 2002-09-24 | 2004-11-18 | Jost-Price Edward Roydon | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
| PL377314A1 (pl) * | 2002-12-20 | 2006-01-23 | Amgen Inc. | Modulatory astmy i zapaleń na tle alergicznym |
| TW200509958A (en) * | 2003-02-14 | 2005-03-16 | Combinatorx Inc | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
| US20040209850A1 (en) * | 2003-04-15 | 2004-10-21 | Theraquest Biosciences, Llc | Methods of treating pain and compositions for use therefor |
| EP1646370A1 (en) | 2003-07-11 | 2006-04-19 | Glaxo Group Limited | Pharmaceutical formulations |
| US20050192261A1 (en) | 2003-09-15 | 2005-09-01 | Jost-Price Edward R. | Methods and reagents for the treatment of immunoinflammatory disorders |
| DE602004031356D1 (de) * | 2003-11-21 | 2011-03-24 | Zalicus Inc | Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen |
| CA2558126A1 (en) | 2004-03-17 | 2005-09-29 | Sosei R&D Ltd. | The treatment of inflammatory disorders and pain using beta-aminoalcohols |
| WO2005102296A2 (en) | 2004-04-23 | 2005-11-03 | Heptagen Limited | Combinations for the treatment of immunoproliferative skin disorders such as psoriasis |
| WO2006027579A2 (en) * | 2004-09-07 | 2006-03-16 | Sosei R & D Ltd. | The treatment of inflammatory disorders and pain |
-
2006
- 2006-04-12 CN CN2006800165347A patent/CN101203214B/zh not_active Expired - Fee Related
- 2006-04-12 DK DK06007632.0T patent/DK1719507T3/da active
- 2006-04-12 DE DE602006015387T patent/DE602006015387D1/de not_active Expired - Lifetime
- 2006-04-12 MX MX2007012794A patent/MX2007012794A/es active IP Right Grant
- 2006-04-12 TW TW095112980A patent/TWI366457B/zh not_active IP Right Cessation
- 2006-04-12 AR AR20060101443A patent/AR054249A1/es not_active Application Discontinuation
- 2006-04-12 ES ES06007632T patent/ES2348920T3/es not_active Expired - Lifetime
- 2006-04-12 AU AU2006233502A patent/AU2006233502B2/en not_active Ceased
- 2006-04-12 MY MYPI20061656A patent/MY147864A/en unknown
- 2006-04-12 SI SI200630807T patent/SI1719507T1/sl unknown
- 2006-04-12 AT AT06007632T patent/ATE473735T1/de active
- 2006-04-12 RS RSP-2010/0442A patent/RS51464B/sr unknown
- 2006-04-12 CA CA2604758A patent/CA2604758C/en not_active Expired - Fee Related
- 2006-04-12 EA EA200702204A patent/EA016082B1/ru not_active IP Right Cessation
- 2006-04-12 US US11/402,255 patent/US8426475B2/en not_active Expired - Fee Related
- 2006-04-12 KR KR1020077026406A patent/KR101355422B1/ko not_active Expired - Fee Related
- 2006-04-12 PT PT06007632T patent/PT1719507E/pt unknown
- 2006-04-12 WO PCT/DK2006/050013 patent/WO2006108424A2/en not_active Ceased
- 2006-04-12 JP JP2008505738A patent/JP5021621B2/ja not_active Expired - Fee Related
- 2006-04-12 EP EP06007632A patent/EP1719507B1/en not_active Expired - Lifetime
- 2006-04-12 PL PL06007632T patent/PL1719507T3/pl unknown
- 2006-04-12 BR BRPI0609361-2A patent/BRPI0609361A2/pt not_active Application Discontinuation
- 2006-04-12 NZ NZ562940A patent/NZ562940A/en not_active IP Right Cessation
-
2007
- 2007-10-08 IL IL186491A patent/IL186491A/en active IP Right Grant
- 2007-10-12 ZA ZA200708748A patent/ZA200708748B/xx unknown
- 2007-11-02 NO NO20075527A patent/NO331211B1/no not_active IP Right Cessation
-
2010
- 2010-10-11 HR HR20100552T patent/HRP20100552T1/hr unknown
- 2010-10-14 CY CY20101100919T patent/CY1111541T1/el unknown
-
2013
- 2013-04-22 US US13/867,796 patent/US20130237607A1/en not_active Abandoned
-
2017
- 2017-02-23 US US15/440,803 patent/US9907765B2/en not_active Expired - Fee Related
-
2018
- 2018-12-21 US US16/228,920 patent/US20190125699A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008535873A5 (enExample) | ||
| US9907765B2 (en) | Treatment of connective tissue diseases of the skin | |
| US20110224196A1 (en) | Treatment of obstructive sleep apnea syndrome with a combination of a carbonic anhydrase inhibitor and an additional active agent | |
| JP2009542657A5 (enExample) | ||
| JP2018199684A5 (enExample) | ||
| RU2019100425A (ru) | Новая доза и препаративная форма | |
| JP2019515909A5 (enExample) | ||
| EP3551166B1 (en) | Topical phenytoin for use in the treatment of peripheral neuropathic pain | |
| WO2011050728A1 (zh) | 一种稳定的雷沙吉兰组合物 | |
| CN115551515A (zh) | 靶向3CLpro的连翘苷及其衍生物和抗新冠应用 | |
| RU2008110933A (ru) | Применение амброксола для лечения риновирусных инфекций | |
| EP3463334B1 (en) | Compositions and methods for protecting organs from ischemia/reperfusion injury associated with transplantation | |
| TWI856977B (zh) | 胺基甲酸酯化合物及包括該化合物之組合於預防、緩解或治療急性壓力症或創傷後壓力症之用途 | |
| CN101757078B (zh) | 一种用于治疗腮腺炎的复方巴布剂及其制备方法 | |
| KR20070059079A (ko) | 경피 페로스피론 투여용 의약적 조성물 | |
| KR20120102214A (ko) | 한방복합 생약 소염 진통 외용제 | |
| HK1091739B (en) | Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin | |
| TH87783B (th) | อุปกรณ์การนำส่งยาผ่านผิวหนังที่มี o-เดสเมทิลเวนลาฟาซีน (odv)หรือเกลือของมัน | |
| JPH0211566B2 (enExample) | ||
| WO2018000098A1 (en) | Treatment of inflammatory myopathies | |
| CA2839122A1 (en) | Intrathecal or epidural administration of 3-[(1s,2s)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol |